NCT01703000已完成不适用
NG PROMUS: A Prospective, Multicenter Trial to Assess the NG PROMUS Everolimus-Eluting Platinum Chromium Coronary Stent System (NG PROMUS Stent System) for the Treatment of Atherosclerotic Lesion(s)
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 100
- 试验地点
- 18
- 主要终点
- Technical Success Rate
研究概览
简要总结
NG PROMUS: A Prospective, Multicenter Trial to Assess the NG PROMUS Everolimus-Eluting Platinum Chromium Coronary Stent System (NG PROMUS Stent System) for the Treatment of Atherosclerotic Lesion(s)
详细描述
To evaluate clinical and peri-procedural angiographic and intravascular ultrasound (IVUS) outcomes for the NG PROMUS Everolimus-Eluting Platinum Chromium Coronary Stent System (NG PROMUS Stent System) in the treatment of subjects with atherosclerotic lesion(s) ≤ 34 mm in length (by visual estimate) in native coronary arteries ≥ 2.50 mm to ≤ 4.0 mm in diameter (by visual estimate)
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject must be at least 18 years of age
- •Subject (or legal guardian) understands the trial requirements and the treatment procedures and provides written informed consent before any trial-specific tests or procedures are performed
- •Subject is eligible for percutaneous coronary intervention (PCI)
- •Subject has symptomatic coronary artery disease with objective evidence of ischemia or silent ischemia
- •Subject is an acceptable candidate for coronary artery bypass grafting (CABG)
- •Subject is willing to comply with all protocol-required follow-up evaluation
- •Angiographic Inclusion Criteria:
- •Target lesion(s) must be located in a native coronary artery with a visually estimated reference vessel diameter (RVD) ≥2.50 mm and ≤4.0 mm
- •Target lesion(s) length must be ≤34 mm (by visual estimate)
- •Target lesion(s) must have visually estimated stenosis ≥50% and <100% with thrombolysis in Myocardial Infarction (TIMI) flow >1 and one of the following (stenosis ≥70%, abnormal fractional flow reserve (FFR), abnormal stress test or imaging stress test, or elevated biomarkers) prior to procedure
- •Coronary anatomy is likely to allow delivery of a study device to the target lesions(s)
- •The first lesion treated must be successfully pre-dilated/pretreated Note: Successful pre-dilatation/pretreatment refers to dilatation with a balloon catheter of appropriate length and diameter, or pretreatment with directional or rotational coronary atherectomy, laser or cutting/scoring balloon with no greater than 50% residual stenosis and no dissection greater than National Heart, Lung, Blood Institute (NHLBI) type C.
排除标准
- •Subject has clinical symptoms and/or electrocardiogram (ECG) changes consistent with acute ST elevation MI (STEMI)
- •Subject has cardiogenic shock, hemodynamic instability requiring inotropic or mechanical circulatory support, intractable ventricular arrhythmias, or ongoing intractable angina
- •Subject has received an organ transplant or is on a waiting list for an organ transplant
- •Subject is receiving or scheduled to receive chemotherapy within 30 days before or after the index procedure
- •Planned PCI (including staged procedures) or CABG after the index procedure
- •Subject previously treated at any time with intravascular brachytherapy
- •Subject has a known allergy to contrast (that cannot be adequately premedicated) and/or the trial stent system or protocol-required concomitant medications (e.g., platinum, platinum-chromium alloy, stainless steel, everolimus or structurally related compounds, polymer or individual components, all P2Y12 inhibitors, or aspirin)
- •Subject has one of the following (as assessed prior to the index procedure):Other serious medical illness (e.g., cancer, congestive heart failure) with estimated life expectancy of less than 24 months; Current problems with substance abuse (e.g., alcohol, cocaine, heroin, etc.);Planned procedure that may cause non-compliance with the protocol or confound data interpretation
- •Subject is receiving chronic (≥72 hours) anticoagulation therapy (i.e., heparin, coumadin) for indications other than acute coronary syndrome
- •Subject has a platelet count <100,000 cells/mm3 or >700,000 cells/mm3
- •Subject has a white blood cell (WBC) count < 3,000 cells/mm3
- •Subject has documented or suspected liver disease, including laboratory evidence of hepatitis
- •Subject is on dialysis or has baseline serum creatinine level >2.0 mg/dL (177µmol/L)
- •Subject has a history of bleeding diathesis or coagulopathy or will refuse blood transfusions
- •Subject has had a history of cerebrovascular accident (CVA) or transient ischemic attack (TIA) within the past 6 months
- •Subject has an active peptic ulcer or active gastrointestinal (GI) bleeding
- •Subject has signs or symptoms of active heart failure (i.e., NYHA class IV) at the time of the index procedure
- •Subject is participating in another investigational drug or device clinical trial that has not reached its primary endpoint
- •Subject intends to participate in another investigational drug or device clinical trial within 12 months after the index procedure
- •Subject with known intention to procreate within 12 months after the index procedure (women of child-bearing potential who are sexually active must agree to use a reliable method of contraception from the time of screening through 12 months after the index procedure)
- •Subject is a woman who is pregnant or nursing (a pregnancy test must be performed within 7 days prior to the index procedure in women of child-bearing potential)
- •Angiographic Exclusion Criteria:
- •Planned treatment of more than 3 lesions.
- •Planned treatment of lesions in more than 2 major epicardial vessels
- •Planned treatment of a single lesion with more than 1 stent
- •Subject has 2 target lesions in the same vessel that are separated by less than 15 mm (by visual estimate)
- •Target lesion(s) is located in the left main
- •Target lesion(s) is located within 3 mm of the origin of the left anterior descending (LAD) coronary artery or left circumflex (LCx) coronary artery by visual estimate.
- •Target lesion(s) is located within a saphenous vein graft or an arterial graft
- •Target lesion(s) will be accessed via a saphenous vein graft or arterial graft
- •Target lesion(s) with a TIMI flow 0 (total occlusion) or TIMI flow 1 prior to guide wire crossing
- •Target lesion(s) treated during the index procedure that involves a complex bifurcation (e.g., bifurcation lesion requiring treatment with more than 1 stent)
- •Target lesion(s) is restenotic from a previous stent implantation or study stent would overlap with a previous stent
- •Subject has unprotected left main coronary artery disease (>50% diameter stenosis)
- •Subject has been treated with any type of PCI (i.e., balloon angioplasty, stent, cutting balloon atherectomy) within 24 hours prior to the index procedure
- •Thrombus, or possible thrombus, present in the target vessel (by visual estimate)
结局指标
主要结局
Technical Success Rate
时间窗: Participants will be followed for the duration of hospital stay, an expected average of 1 day
Technical success is defined as successful delivery and deployment of the study stent to the target lesion, without balloon rupture or stent embolization, and post-procedure diameter stenosis of \<30% assessed in 2 near-orthogonal projections with TIMI 3 flow in the target lesion, as visually assessed by the physician
次要结局
- All Death/MI/TVR Rate(Participants will be followed for the duration of hospital stay, an expected average of 1 day and at 30 days)
- Target Lesion Revascularization (TLR) Rate(Participants will be followed for the duration of hospital stay, an expected average of 1 day and at 30 days)
- Target Lesion Failure (TLF) Rate(Participants will be followed for the duration of hospital stay, an expected average of 1 day and at 30 days)
- Target Vessel Revascularization (TVR) Rate(Participants will be followed for the duration of hospital stay, an expected average of 1 day and at 30 days)
- Target Vessel Failure (TVF) Rate(Participants will be followed for the duration of hospital stay, an expected average of 1 day and at 30 days)
- Myocardial Infarction (MI, Q-wave and Non-Q-wave) Rate(Participants will be followed for the duration of hospital stay, an expected average of 1 day and at 30 days)
- Cardiac Death Rate(Participants will be followed for the duration of hospital stay, an expected average of 1 day and at 30 days)
- Non-cardiac Death Rate(Participants will be followed for the duration of hospital stay, an expected average of 1 day and at 30 days)
- All Death Rate(Participants will be followed for the duration of hospital stay, an expected average of 1 day and at 30 days)
- Cardiac Death or MI Rate(Participants will be followed for the duration of hospital stay, an expected average of 1 day and at 30 days)
- All Death or MI Rate(Participants will be followed for the duration of hospital stay, an expected average of 1 day and at 30 days)
- Stent Thrombosis Rate (by Academic Research Consortium [ARC] Definitions)(Participants will be followed for the duration of hospital stay, an expected average of 1 day and at 30 days)
- Clinical Procedural Success Rate(Participants will be followed for the duration of hospital stay, an expected average of 1 day)
- In-stent Percent Diameter Stenosis (%DS)(Participants will be followed for the duration of hospital stay, an expected average of 1 day)
- In-segment Percent Diameter Stenosis (%DS)(Participants will be followed for the duration of hospital stay, an expected average of 1 day)
- In-stent Minimum Lumen Diameter (MLD)(Participants will be followed for the duration of hospital stay, an expected average of 1 day)
- In-segment Minimum Lumen Diameter (MLD)(Participants will be followed for the duration of hospital stay, an expected average of 1 day)
- Acute Gain(Participants will be followed for the duration of hospital stay, an expected average of 1 day)
- Vessel Area(Participants will be followed for the duration of hospital stay, an expected average of 1 day)
- Stent Area(Participants will be followed for the duration of hospital stay, an expected average of 1 day)
- Lumen Area(Participants will be followed for the duration of hospital stay, an expected average of 1 day)
- Vessel Volume(Participants will be followed for the duration of hospital stay, an expected average of 1 day)
- Stent Volume(Participants will be followed for the duration of hospital stay, an expected average of 1 day)
- Lumen Volume(Participants will be followed for the duration of hospital stay, an expected average of 1 day)
- Incomplete Apposition(Participants will be followed for the duration of hospital stay, an expected average of 1 day)
- Percent Net Volume Obstruction(Participants will be followed for the duration of hospital stay, an expected average of 1 day)
- Longitudinal Stent Deformation(Participants will be followed for the duration of hospital stay, an expected average of 1 day)
研究者
研究点 (18)
Loading locations...
相似试验
已完成
3 期
The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of Long De Novo Coronary Artery Lesions (PLATINUM LL)Coronary Artery DiseaseNCT01500434Boston Scientific Corporation102
已完成
不适用
The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions in Small VesselsCoronary Artery DiseaseNCT01498692Boston Scientific Corporation94
已完成
3 期
PLATINUM Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions-Pharmacokinetics (PLATINUM PK)Coronary Artery DiseaseNCT01510327Boston Scientific Corporation22
已完成
3 期
The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery LesionsCoronary Artery DiseaseNCT00823212Boston Scientific Corporation1,530
Unknown
不适用
Trial to Assess the Everolimus-Eluting Coronary Stent System (PROMUS Element) for Coronary RevascularizationIschemic Heart DiseaseCoronary Artery StenosisNCT01342822European Cardiovascular Research Center2,980